NCT05687890 - A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease | Biotech Hunter

Enrollment

255

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

April 30, 2025

Conditions

Diabetic Kidney DiseaseIgA Nephropathy

Interventions

DRUG

Placebo of SC0062

Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period

DRUG

SC0062 low dose

Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period

DRUG

SC0062 medium dose

Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period

DRUG

SC0062 high dose

Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period

Trial Locations (1)

310003

79 Qingchun Rd.,Shangcheng District, Hangzhou